|
|
|
|
||
Re: Less than 400k shares traded; what's up PGENers?come on now choo choo. I did not take you as being a disingenuous individual but I have been wrong before. Your posts which i will list below speak to a belief the stock was heading higher based on data. Pay particular attention to the last post copied where you believed the stock could be $5 by year's end
Re: Effective floatLegitimate point. Let's "hope" that with at least two data releases in Q-4 that the stock makes a run to much higher levels. . .. . . like it did two years ago when it ran from the $2 level to over $10 from June to January. Even the skeptics would have to admit that the company has made a lot of progress since then and the upcoming data releases. . . .. . if truly "compelling" . . . .. could give the stock a nice lift from these levels. The Rube is right on one thing imho . . .. . Helen was exceptionally direct about the fact that the data was "compelling" and her comparisons to other cancer treatment approvals with 15% - 18% response rates has to be a clue that she thinks she has the goods. And then clearly confirming the increased length of time between surgeries for RRP patients . . . . . and perhaps some patients being "cured" . . .. . . you don't talk like that unless you have the goods . . . .. . . or you are a carnival barker. Helen is not a CB.
Re: PRGN-2012 - recent history of changes.. . . another wager for Mabel and Ubmmgwith the stock at $2.75 . . . .. I will bet the stock trades above $3 . . . . . . before it trades at $2.50 . . .. . Should be a wager the bears / skeptics will want to make. LMK how heavy you gents want to go.
$2.38 - $.29 or 10.85% on volume of only 256K as of 10:50 a.m. - another buyingAverage daily volume past ten days is 1.3M shares. The drop today on no news looks like another buying opportunity.
Re: $2.38 - $.29 or 10.85% on volume of only 256K as of 10:50 a.m. - another buyingimho . . . . the most likely asset to be partnered first is the TD-1 program . .. . . which dearest Mabel has phase 2 data. $25M and a royalty would at least represent bona fide "third party" validation of the science. I would hope we don't partner other assets until we have "compelling" data . . .. so compelling we would secure favorable partnership terms, etc. Re PRGN-2012 . . . . thank you for sharing the blog updates. . . but as you note . . . they aren't "data". Please note that Helen was very specific in her recent fireside chat re cancer treatments that were approved with 15% - 30% response rates . . . . and as this particular disease has no good standard of care treatment except repeated surgeries . . . . . . . and she said "what if some patients were cured . . . . what would people think of that ?" . . . . . . . I agree with THE Rube . . . . . . Helen has signaled that she is more than "excited" . .. . . . she believes the data is "compelling" . . . . . she has heretofore practiced "under-promise and over-deliver" . . . . . . and I think she'll start to get the Street's attention this November. Not to nit pick . . .. but you missed my point about the UltrPorator . . .. . yes others can produce CAR-T's over night . . . . . . but I doubt they will be able to compete on price with PGEN . . . . .. . yes price doesn't matter unless you have efficacy . . . . . let's see if the AML data starts to show more efficacy. And no where did I say $10 was my six month price target. But I do think the fundamentals are better than they were two years ago and if we secure some bona fide "sponsorship" . . . . . we could be north of $5 by year end and maybe $1 or $2 higher a few months later. How the next equity raise is handled will be important. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
51519 | Re: Less than 400k shares traded; what's up PGENers? | Mabel | 0 | 10/19/2022 12:56:07 PM |
51520 | Re: Less than 400k shares traded; what's up PGENers? | Graham&Dodd | 0 | 10/19/2022 1:15:25 PM |